PNP THERAPEUTICS, INC.

GeoVax Advances Gedeptin Gene Therapy for Solid Tumors with Expanded Patent Portfolio and Promising Clinical Data

23 days ago

• GeoVax has strengthened its Gedeptin therapy platform with newly allowed patent claims covering the synergistic combination of gene therapy with radiation for treating various solid tumors. • Clinical data presented at AACR 2025 demonstrated Gedeptin's safety profile and efficacy in heavily pretreated head and neck cancer patients, with median progression-free and overall survival of 7.0 months. • The company is advancing to a Phase 2 trial combining Gedeptin with pembrolizumab (Keytruda) as a neoadjuvant therapy for relapsed head and neck cancer, leveraging potential synergy with immune checkpoint inhibitors.